Reuters Market Eye - The NSE Pharma index falls 0.93 percent after the government formally notified a new drug pricing policy designed to increase the number of drugs deemed essential that are subject to price caps.
The policy, which will curtail prices of costly brands sold by domestic and international drugmakers, was approved by the government in November. Glenmark Pharmaceuticals Ltd falls 1.68 percent, Ranbaxy Laboratories Ltd slips 1.65 percent, while Dr.Reddy's Laboratories Ltd declines 1.68 percent.
Cipla Ltd is down 0.94 percent and Lupin Ltd falls 1.04 percent. (Reporting by Himank Sharma)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app